Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers

Por Migliaccio, Ilenia, Malorni, Luca, Hart, Christopher D, Guarducci, Cristina, Di Leo, Angelo
Publicado no BMC Med (2015)

Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?

Por Turner, Natalie, Pestrin, Marta, Galardi, Francesca, De Luca, Francesca, Malorni, Luca, Di Leo, Angelo
Publicado em 2014

Development of resistance to targeted therapies transforms the clinically-associated molecular profile subtype of breast tumor xenografts

Por Creighton, Chad J., Massarweh, Suleiman, Huang, Shixia, Tsimelzon, Anna, Shou, Jiang, Malorni, Luca, Hilsenbeck, Susan G., Osborne, C. Kent, Schiff, Rachel
Publicado em 2008

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with...

Por Malorni, Luca, Piazza, Silvano, Ciani, Yari, Guarducci, Cristina, Bonechi, Martina, Biagioni, Chiara, Hart, Christopher D., Verardo, Roberto, Leo, Angelo Di, Migliaccio, Ilenia
Publicado no Oncotarget (2016)

Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis

Por Barba, Maddalena, Yang, Li, Schünemann, Holger J, Sperati, Francesca, Grioni, Sara, Stranges, Saverio, Westerlind, Kim C, Blandino, Giovanni, Gallucci, Michele, Lauria, Rossella, Malorni, Luca, Muti, Paola
Publicado em 2009

Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer

Por Migliaccio, Ilenia, Wu, Meng-Fen, Gutierrez, Carolina, Malorni, Luca, Mohsin, Syed K., Allred, D. Craig, Hilsenbeck, Susan G., Osborne, C. Kent, Weiss, Heidi, Lee, Adrian V.
Publicado em 2009

TransCONFIRM: Identification of a genetic signature of response to fulvestrant in advanced hormone receptor positive breast cancer

Por Jeselsohn, Rinath, Barry, William T., Migliaccio, Ilenia, Biagioni, Chiara, Zhao, Jin, De Tribolet-Hardy, Jonas, Guarducci, Cristina, Bonechi, Martina, Laing, Naomi, Winer, Eric P., Brown, Myles, Di Leo, Angelo, Malorni, Luca
Publicado no Clin Cancer Res (2016)

Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial

Por Leo, Angelo Di, Jerusalem, Guy, Petruzelka, Lubos, Torres, Roberto, Bondarenko, Igor N., Khasanov, Rustem, Verhoeven, Didier, Pedrini, José L., Smirnova, Iya, Lichinitser, Mikhail R., Pendergrass, Kelly, Malorni, Luca, Garnett, Sally, Rukazenkov, Yuri, Martin, Miguel
Publicado em 2013

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Por Malorni, Luca, Giuliano, Mario, Migliaccio, Ilenia, Wang, Tao, Creighton, Chad J., Lupien, Mathieu, Fu, Xiaoyong, Hilsenbeck, Susan G., Healy, Nuala, De Angelis, Carmine, Mazumdar, Abhijit, Trivedi, Meghana V., Massarweh, Suleiman, Gutierrez, Carolina, De Placido, Sabino, Jeselsohn, Rinath, Brown, Myles, Brown, Powel H., Osborne, C. Kent, Schiff, Rachel
Publicado no Mol Cancer Res (2016)